Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Researchers at the Kennedy Institute demonstrate that the drug decitabine can boost regulatory T cell responses.

T cell © Shutterstock

A study by Dr I-Shu Huang and colleagues in Professor Richard Williams’s Group published in PNAS shows that decitabine, a drug currently approved for treatment of cancer patients, can boost regulatory T cells in animal models. As robust regulatory T cells have the capacity to suppress immune-driven inflammation, the findings offer a treatment pathway for chronic inflammatory diseases like rheumatoid arthritis (RA). 

Richard said: “RA is characterised by a deficit in fully functional regulatory T cells. But there is evidence that DNA-methylation inhibitors, used for treatment of cancer, increase regulatory T cell responses in patients. This led us to question whether short-term treatment of autoimmune arthritis with DNA methylation inhibitors could restore numbers of regulatory T cells, leading to long-term suppression of disease."  

Of three DNA methylation inhibitors tested in an animal model of rheumatoid arthritis, decitabine was the most effective, producing a sustained therapeutic effect. The researchers observed a profound and rapid decrease in numbers of pathogenic Th1 and Th17 cells in decitabine treated mice and an increase in numbers of regulatory T cells, particularly in the inflamed joint. 

“This study identifies a path toward resetting tolerance in autoimmune disease using a repurposed drug,” said Richard. “However, decitabine acts in a non-specific way and therefore is likely to have many off-target effects when used in a chronic disease like rheumatoid arthritis. Further research would aim to identify more selective epigenetic drugs to restore immune homeostasis.” 

Similar stories

New hope for patients after vedolizumab found effective to treat Chronic Pouchitis

A new study led by Oxford researchers has found vedolizumab can induce remission in patients who have chronic pouchitis after surgery for ulcerative colitis.

New approach to nail bed injury surgery could significantly cut NHS costs

According to a new Oxford study, changing clinical practice for finger injuries in children could save the NHS £720,000 per year.

Furniss Group paper wins journal award

Editors at the Journal of Hand Surgery have recognised the Furniss Group with an award for the best paper published in the Journal in 2022. The Editor’s Award recognises research with scientific importance, outstanding study stringency, and a high academic standard.

NIHR Fellowships awarded to NDORMS researchers

Congratulations to Eileen Morrow and Mae Chester-Jones who have received NIHR Doctoral Fellowships

ORUK Early Career Research Fellowship awarded to NDORMS researcher

Congratulations to Jack Tu who has been awarded an Orthopaedic Research UK Early Career Research Fellowship to explore the cause of knee pain after total knee replacement.

OCTRU - delivering answers to important clinical questions

The Oxford Clinical Trials Research Unit (OCTRU) has received NIHR benchmarking results and offers excellent value for money according to the report